Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITHRIVE anaemia trial in adult survivors of critical illness
ACTRN12621000595819Phase 3Recruiting
- Sponsor
- Fiona Stanley Hospital
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ferric carboxymaltose and epoetin alfa in anaemia, sponsored by Fiona Stanley Hospital. Primary endpoints: Days alive and at home by Day 90 and Treatment delivery feasibility. Started Oct 2021; status: recruiting.
02
Drugs
ferric carboxymaltoseepoetin alfa
03
Conditions
anaemia
Beyond the preview
Go deeper on ACTRN12621000595819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000595819.